Disorder of eye
Ollin Biosciences Launches with $100M to Challenge Roche in Eye Disease Market
Ollin Biosciences; Roche; eye disease; biotech; VEGF-A; Ang2; wet AMD; diabetic macular edema; clinical trial; OLN324; Vabysmo
Roche Pledges Nearly $300M to Establish New Vabysmo Production Plant in China
Roche; Vabysmo; biopharmaceutical manufacturing; Shanghai; China; investment; eye disease treatment; plant construction; localization; green energy
Beacon’s rare eye disease gene therapy signals vision function improvements in early phase 2 data
XLRP, gene therapy, laru-zova, visual function, rare eye disease, Phase 2 trial, DAWN trial, vision improvement, low light vision
J&J’s $130M gene therapy bet flunks rare retinal disease trial
Johnson & Johnson, gene therapy, bota-vec, X-linked retinitis pigmentosa, Phase 3 failure, vision loss treatment, rare eye disease, $130 million investment